

## Contents

|                                    |               |
|------------------------------------|---------------|
| <b>About the Author</b>            | <i>xiii</i>   |
| <b>Foreword</b>                    | <i>xv</i>     |
| <b>Preface</b>                     | <i>xvii</i>   |
| <b>Abbreviations</b>               | <i>xix</i>    |
| <b>About the Companion Website</b> | <i>xxxiii</i> |

|          |                                                                                            |           |
|----------|--------------------------------------------------------------------------------------------|-----------|
| <b>1</b> | <b>Canine Mesenchymal Stem Cells Sources, Properties, and Regulations for Clinical Use</b> | <b>1</b>  |
| 1.1      | Introduction                                                                               | 1         |
| 1.2      | Understanding the Stem Cell                                                                | 3         |
| 1.2.1    | MSCs Stemness or Stromalness?                                                              | 4         |
| 1.2.2    | MSCs Plasticity                                                                            | 6         |
| 1.2.3    | MSCs Mobilization and Homing                                                               | 7         |
| 1.2.4    | Anti-inflammatory and Immunomodulatory Actions                                             | 8         |
| 1.2.5    | Antimicrobial Actions                                                                      | 8         |
| 1.3      | Sources of Dog MSCs for Proliferation                                                      | 9         |
| 1.4      | Why Do We Need to Culture Mesenchymal Stem Cells?                                          | 10        |
| 1.5      | Why to Characterize MSCs?                                                                  | 11        |
| 1.6      | Factors Affecting MSCs Therapeutic Outcome                                                 | 12        |
| 1.7      | Stem Cell Regulations in Research and Therapeutics                                         | 13        |
|          | References                                                                                 | 15        |
| <b>2</b> | <b>Osteoarthritis</b>                                                                      | <b>27</b> |
| 2.1      | Introduction                                                                               | 27        |
| 2.2      | Predisposing Factors                                                                       | 28        |
| 2.3      | OA Pathogenesis                                                                            | 30        |
| 2.3.1    | OA Mediated Through Cartilage                                                              | 30        |
| 2.3.2    | OA Mediated Through Synovitis                                                              | 34        |
| 2.3.3    | Subchondral Bone Involvement                                                               | 36        |

|         |                                                       |    |
|---------|-------------------------------------------------------|----|
| 2.4     | MSCs and Their Potential Therapeutic Role in OA       | 37 |
| 2.4.1   | MSCs Chondrogenic Studies and <i>Ex Vivo</i> Findings | 37 |
| 2.4.1.1 | Culture Technique                                     | 38 |
| 2.4.1.2 | Local Microenvironment                                | 39 |
| 2.4.1.3 | Source of MSCs                                        | 39 |
| 2.4.1.4 | MSCs Transplantation Techniques and Drug Reactions    | 39 |
| 2.4.1.5 | Therapeutic Properties of MSCs                        | 40 |
| 2.5     | <i>In Vivo</i> MSCs Studies                           | 42 |
| 2.5.1   | Preclinical Experimental Studies                      | 42 |
| 2.5.1.1 | Chondral Lesions                                      | 42 |
| 2.5.1.2 | Osteochondral Defects                                 | 46 |
| 2.5.1.3 | Cruciate Ligament Resection Model                     | 51 |
| 2.5.1.4 | Menisectomy Model                                     | 54 |
| 2.5.2   | Clinical Studies                                      | 55 |
| 2.5.2.1 | Hip Joint OA                                          | 56 |
| 2.5.2.2 | Elbow OA                                              | 61 |
| 2.5.2.3 | Stifle Joint OA                                       | 66 |
| 2.5.2.4 | Multiple Joint OA                                     | 66 |
| 2.5.2.5 | Hip Dysplasia Induced OA                              | 72 |
|         | References                                            | 73 |

### **3 MSCs in Canine Bone Tissue Engineering 97**

|         |                                              |     |
|---------|----------------------------------------------|-----|
| 3.1     | Introduction                                 | 97  |
| 3.2     | Mesenchymal Stem Cells and Bone Regeneration | 99  |
| 3.2.1   | MSCs <i>In Vitro</i> Osteogenesis            | 100 |
| 3.2.1.1 | Osteogenic Growth Factors/Chemicals          | 101 |
| 3.2.1.2 | Effect of Source                             | 103 |
| 3.2.1.3 | Scaffold and MSCs Osteogenesis               | 105 |
| 3.2.1.4 | Breed-Wise Differences                       | 106 |
| 3.2.2   | MSCs Osteogenesis                            | 107 |
| 3.3     | <i>In Vivo</i> Studies                       | 107 |
| 3.3.1   | Preclinical Experimental Studies in Dogs     | 108 |
| 3.3.1.1 | Femoral Bone Defect Model                    | 109 |
| 3.3.1.2 | Radial Bone Defect Model                     | 117 |
| 3.3.1.3 | Ulnar Bone Defect Model                      | 118 |
| 3.3.1.4 | Tibial Bone Defect Model                     | 119 |
| 3.3.1.5 | Mandibular Bone Defect Models                | 120 |
| 3.3.2   | Dog <i>In Vivo</i> Clinical Studies          | 125 |
| 3.3.2.1 | Augmentation of Normal Bone Healing          | 128 |
| 3.3.2.2 | Nonunion Radial Fracture                     | 128 |
| 3.3.2.3 | Nonunion Radial/Ulnar Fracture               | 129 |
| 3.3.2.4 | Nonunion Femoral Fracture                    | 130 |
|         | References                                   | 131 |

|          |                                                                          |            |
|----------|--------------------------------------------------------------------------|------------|
| <b>4</b> | <b>Muscle, Tendon, and Ligament Affections</b>                           | <b>149</b> |
| 4.1      | Introduction                                                             | 149        |
| 4.2      | Why Mesenchymal Stem Cells and Not Tendon Stem/Progenitor Cells (TSPCs)? | 152        |
| 4.2.1    | Tenogenic Markers                                                        | 154        |
| 4.2.2    | <i>In Vitro</i> Studies on MSCs Tenogenesis                              | 155        |
| 4.2.2.1  | Tenogenic Differentiation                                                | 155        |
| 4.2.2.2  | <i>In Vitro</i> Tendon Healing Model                                     | 158        |
| 4.3      | <i>In Vivo</i> Studies                                                   | 160        |
| 4.3.1    | Tendon Repair Models                                                     | 160        |
| 4.3.1.1  | Intrasynovial Second and Fifth Flexor Digitorum Profundus Model          | 160        |
| 4.3.1.2  | Rotator Cuff Injury Model                                                | 165        |
| 4.3.1.3  | Achilles Tendon Model                                                    | 167        |
| 4.3.2    | Clinical Tendinopathies                                                  | 167        |
| 4.3.3    | Ligament Repair Models                                                   | 170        |
| 4.3.3.1  | Partial CrCL Tear Studies                                                | 171        |
| 4.3.3.2  | Complete CrCL Tear Studies                                               | 173        |
| 4.4      | Muscle Studies                                                           | 175        |
| 4.4.1    | MSCs <i>In Vitro</i> Myogenic Differentiation                            | 175        |
| 4.4.2    | <i>In Vivo</i> Clinical Muscle Injury Studies                            | 176        |
| 4.4.3    | Duchenne's Muscle Dystrophy (DMD)                                        | 179        |
|          | References                                                               | 180        |
| <b>5</b> | <b>Peripheral Nerve Affections</b>                                       | <b>197</b> |
| 5.1      | Introduction                                                             | 197        |
| 5.2      | Peripheral Nerve Injury                                                  | 199        |
| 5.2.1    | Natural Recovery of Peripheral Nerves                                    | 201        |
| 5.2.1.1  | Role of Schwann Cells and Macrophages                                    | 203        |
| 5.2.2    | Surgical Procedure and Limitations Thereof                               | 205        |
| 5.3      | Why MSCs and Not Schwann Cells for Nerve Regeneration                    | 206        |
| 5.4      | <i>In Vivo</i> Peripheral Nerve Injury Studies                           | 207        |
| 5.4.1    | Dog Peripheral Nerve Resection Models                                    | 209        |
| 5.4.1.1  | Sciatic Nerve Repair                                                     | 209        |
| 5.4.1.2  | Facial Nerve Repair                                                      | 212        |
| 5.4.1.3  | Ulnar Nerve                                                              | 214        |
|          | References                                                               | 216        |
| <b>6</b> | <b>Central Nervous System Affections</b>                                 | <b>225</b> |
| 6.1      | Introduction                                                             | 225        |
| 6.2      | CNS Intrinsic Regeneration Potential                                     | 226        |
| 6.3      | Exogenous Stem Cell Therapy                                              | 227        |
| 6.3.1    | <i>In Vitro</i> MSCs Neurogenic Studies                                  | 228        |

|         |                                                                 |     |
|---------|-----------------------------------------------------------------|-----|
| 6.3.1.1 | Neural-Induced MSCs Morphology and Expression                   | 228 |
| 6.3.1.2 | Expression and Secretion Potential of Neural-Induced MSCs       | 229 |
| 6.3.2   | Contradicted View-Point Toward MSCs Neural-Like Differentiation | 233 |
| 6.3.3   | <i>In Vivo</i> Studies                                          | 234 |
| 6.3.3.1 | MSCs Therapeutic Mechanisms                                     | 235 |
| 6.3.3.2 | Meningoencephalomyelitis of Unknown Origin (MUO)                | 237 |
| 6.3.3.3 | Canine Distemper (CD)                                           | 238 |
| 6.3.3.4 | Spinal Cord Injury (SCI)                                        | 242 |
|         | References                                                      | 270 |

## **7 Myocardial and Valvular Diseases 287**

|         |                                                 |     |
|---------|-------------------------------------------------|-----|
| 7.1     | Introduction                                    | 287 |
| 7.2     | Why MSCs in Cardiac Diseases?                   | 288 |
| 7.2.1   | Differentiation                                 | 289 |
| 7.2.1.1 | Microenvironment Modulation                     | 289 |
| 7.2.1.2 | Genetic Modulation                              | 292 |
| 7.2.2   | MSCs Stromalness for Cardiac Regeneration       | 294 |
| 7.3     | <i>In Vivo</i> MSCs Therapeutic Studies in Dogs | 296 |
| 7.3.1   | MSCs Transplantation                            | 298 |
| 7.3.2   | Cellular Concentration and Transplantation Rate | 299 |
| 7.3.3   | Cellular Distribution                           | 300 |
| 7.3.4   | Cellular Differentiation                        | 301 |
| 7.3.5   | Myocardial Infarction (MI)                      | 302 |
| 7.3.5.1 | Acute MI                                        | 303 |
| 7.3.5.2 | Subacute MI                                     | 307 |
| 7.3.5.3 | Chronic MI                                      | 308 |
| 7.3.6   | MSCs as Biological Pacemaker                    | 310 |
| 7.3.6.1 | <i>In Vivo</i> Studies                          | 311 |
| 7.3.7   | Dilatation Cardiomyopathy (DCM)                 | 314 |
| 7.3.7.1 | <i>In Vivo</i> Studies                          | 315 |
| 7.3.8   | Chronic Chagas Cardiomyopathy                   | 318 |
| 7.3.9   | Valvular Diseases                               | 319 |
|         | References                                      | 321 |

## **8 Oral and Esophageal Affections 341**

|       |                      |     |
|-------|----------------------|-----|
| 8.1   | Introduction         | 341 |
| 8.2   | Oral Mucosal Ulcers  | 344 |
| 8.3   | Periodontal Disease  | 347 |
| 8.3.1 | Fenestration Defects | 355 |
| 8.3.2 | Intrabony Defects    | 356 |
| 8.3.3 | Furcation Defects    | 358 |

|           |                                                             |            |
|-----------|-------------------------------------------------------------|------------|
| 8.4       | Maxillary Alveolar Bone Cleft Model                         | 359        |
| 8.5       | Peri-implant Defect Models                                  | 360        |
| 8.6       | Esophagus                                                   | 362        |
| 8.6.1     | Esophageal Ulceration                                       | 363        |
| 8.6.2     | Esophageal Resection                                        | 365        |
|           | References                                                  | 366        |
| <b>9</b>  | <b>Inflammatory Bowel Disease and Anal Furunculosis</b>     | <b>377</b> |
| 9.1       | Introduction                                                | 377        |
| 9.2       | Why Mesenchymal Stem Cells                                  | 382        |
| 9.3       | <i>In Vivo</i> Studies                                      | 384        |
| 9.3.1     | Inflammatory Bowel Disease (IBD)                            | 384        |
| 9.3.2     | Anal Furunculosis (AF)                                      | 388        |
|           | References                                                  | 389        |
| <b>10</b> | <b>Liver Affections</b>                                     | <b>397</b> |
| 10.1      | Introduction                                                | 397        |
| 10.2      | Regenerative Medicine in Canine Hepatology                  | 398        |
| 10.2.1    | Why Mesenchymal Stem Cells for Liver Regeneration           | 399        |
| 10.2.2    | <i>In Vitro</i> MSCs Hepatocyte-Like Cell Differentiation   | 400        |
| 10.2.2.1  | Microenvironment Modifications                              | 400        |
| 10.2.2.2  | 3D Culture of MSCs for Hepatocyte-Like Cell Differentiation | 402        |
| 10.2.2.3  | Genetic Manipulation of MSCs                                | 403        |
| 10.3      | <i>In Vivo</i> Liver Regenerative Studies                   | 404        |
| 10.3.1    | Dog Hepatic Injury Models                                   | 405        |
| 10.3.1.1  | Acute Liver Injury Models                                   | 405        |
| 10.3.1.2  | Hepatic Fibrosis Models                                     | 407        |
| 10.4      | Hepatocutaneous Syndrome                                    | 409        |
|           | References                                                  | 411        |
| <b>11</b> | <b>Lung Affections</b>                                      | <b>419</b> |
| 11.1      | Introduction                                                | 419        |
| 11.2      | MSCs Potential Therapeutic Effects                          | 421        |
| 11.3      | <i>In Vivo</i> Studies                                      | 423        |
| 11.3.1    | Acute Respiratory Distress Syndrome (ARDS)                  | 423        |
| 11.3.2    | Radiation-Induced Lung Injury                               | 427        |
|           | References                                                  | 428        |
| <b>12</b> | <b>Renal Insufficiency and Urinary Bladder Affections</b>   | <b>435</b> |
| 12.1      | Introduction                                                | 435        |
| 12.2      | <i>In Vitro</i> Renal Studies                               | 437        |
| 12.3      | <i>In Vivo</i> Renal Studies                                | 441        |

|          |                                  |     |
|----------|----------------------------------|-----|
| 12.3.1   | Experimental Studies             | 441 |
| 12.3.1.1 | Drug-Induced Acute Kidney Injury | 444 |
| 12.3.1.2 | Ischemic AKI                     | 446 |
| 12.3.1.3 | Chronic Kidney Disease Model     | 448 |
| 12.3.2   | Clinical Studies                 | 449 |
| 12.3.2.1 | Chronic Kidney Disease           | 449 |
| 12.3.2.2 | Renal Fanconi Syndrome           | 449 |
| 12.4     | Urinary Bladder                  | 450 |
| 12.4.1   | <i>In Vivo</i> Studies           | 451 |
|          | References                       | 453 |

## **13 Skin Wounds and Atopic Dermatitis 461**

|          |                                                      |     |
|----------|------------------------------------------------------|-----|
| 13.1     | Introduction                                         | 461 |
| 13.2     | <i>In Vivo</i> Skin Wound-Healing Studies Using MSCs | 462 |
| 13.2.1   | Preclinical Experimental Studies                     | 463 |
| 13.2.2   | Clinical Studies                                     | 466 |
| 13.2.2.1 | Acute Wounds                                         | 466 |
| 13.2.2.2 | Chronic Wounds                                       | 470 |
| 13.3     | Atopic Dermatitis (AD)                               | 472 |
| 13.3.1   | <i>Ex Vivo</i> Studies                               | 473 |
| 13.3.2   | <i>In Vivo</i> Studies                               | 474 |
| 13.3.2.1 | Experimental Studies                                 | 474 |
| 13.3.2.2 | Clinical Studies                                     | 477 |
|          | References                                           | 479 |

## **14 Diabetes 487**

|          |                                                     |     |
|----------|-----------------------------------------------------|-----|
| 14.1     | Introduction                                        | 487 |
| 14.2     | <i>In Vitro</i> Studies                             | 490 |
| 14.2.1   | MSCs Trans-differentiation into IPCs                | 491 |
| 14.2.1.1 | Microenvironment Manipulation                       | 491 |
| 14.2.1.2 | Genetic Manipulation                                | 496 |
| 14.2.1.3 | Combined Microenvironment and Genetic Modifications | 497 |
| 14.2.1.4 | Secretome-Based Pro-islet Cell-Like Response        | 498 |
| 14.2.2   | MSCs Versus PSCs to Form IPCs                       | 498 |
| 14.3     | <i>In Vivo</i> Studies                              | 499 |
| 14.3.1   | Experimental Studies                                | 500 |
| 14.3.1.1 | Transplantation of Transfected Cells                | 500 |
| 14.3.1.2 | Transplantation of Chemical-Induced Cells           | 502 |
| 14.3.2   | Clinical Studies                                    | 503 |
|          | References                                          | 506 |

|           |                                                                |            |
|-----------|----------------------------------------------------------------|------------|
| <b>15</b> | <b>Corneal Ulcers and Keratoconjunctivitis Sicca</b>           | <b>517</b> |
| 15.1      | Introduction                                                   | 517        |
| 15.2      | Mesenchymal Stem Cells (MSCs) Versus Corneal/Limbal Stem Cells | 518        |
| 15.3      | Corneal Affections                                             | 521        |
| 15.3.1    | Corneal Ulcer                                                  | 522        |
| 15.3.1.1  | <i>In Vivo</i> Studies                                         | 523        |
| 15.3.1.2  | Corneal Superficial Keratitis (Pannus)                         | 525        |
| 15.3.1.3  | Descemetocoele                                                 | 526        |
| 15.4      | Keratoconjunctivitis Sicca (KCS)                               | 527        |
| 15.4.1    | Route of MSCs Transplantation                                  | 530        |
| 15.4.2    | Therapeutic Outcome                                            | 531        |
|           | References                                                     | 532        |
|           | <b>Index</b>                                                   | <b>543</b> |

